Recent Updates
Recently added Catalysts

TX000045

Phase 2

Hypertension, Pulmonary | Small molecule | Cardiovascular |Tectonic Therapeutic, Inc. Common Stock|Last Updated: Jul 27, 2026

Target and mechanism

Molecular targetRXFP1
Target classGpcr
ModalitySmall molecule

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment25

FDA Designations

No designations recorded

Clinical trial landscape

TX000045 · 1 trial · 2 indications

Phase 2 1
NCT07473700Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung DiseaseHypertension, Pulmonary
RECRUITING25 Analytics
PHASE2RECRUITING
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
Hypertension, Pulmonary
NCT0747370025
Unlock trial analytics

Study Endpoints

Primary Endpoints

Mean Change from Baseline in PVR up to 16 Weeks
Baseline up to 16 weeks
Number of Participants with Adverse Events (AEs), Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs)
Baseline up to 21 weeks
Number of Participants with Clinically Significant Changes from Baseline in Safety Laboratory Assessments, 12-Lead Electrocardiogram (ECG) Assessments and Vital Sign Assessments
Baseline up to 21 weeks

Secondary Endpoints

Mean Change from Baseline in Mean Pulmonary Arterial Pressure (mPAP) up to 21 Weeks
Baseline up to 21 weeks
Mean Change from Baseline in Hemodynamic Parameter: Pulmonary Capillary Wedge Pressure (PCWP)
Baseline up to 21 weeks
Mean Change from Baseline in Hemodynamic Parameter: Cardiac Output (CO)
Baseline up to 21 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
TX000045 300 mgEXPERIMENTALParticipants will receive subcutaneous (SC) injection of TX000045 at a dose of 300 milligrams (mg) every 4 weeks (Q4W) from Week 1 up to Week 13.

Interventions

NameTypeDescription
TX000045DRUGSubcutaneous Injection.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * Confirmed diagnosis of ILD based on imaging: chest computed tomography (CT) performed within the past 12 months with fibrotic lung disease (greater than or equal to (\>=) 10 percent (%) lung parenchyma with fibrosis) consistent with idiopathic interstitial pneumonia, ILD in as...

Countries:United StatesPolandRomaniaSerbiaSouth KoreaSpain
Unlock Eligibility Criteria

Frequently asked questions about TX000045

What is TX000045 used for?

TX000045 is an investigational small molecule being developed for pulmonary hypertension, specifically pulmonary hypertension due to interstitial lung disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.

What does TX000045 target?

TX000045 targets RXFP1, a G protein-coupled receptor (GPCR). By modulating this receptor, the drug is being studied for its potential effects in treating pulmonary hypertension associated with interstitial lung disease.

Who is developing TX000045?

TX000045 is being developed by Tectonic Therapeutic, Inc., a biopharmaceutical company. The company's common stock trades under the ticker symbol TECX on the stock market.

What phase is TX000045 in?

TX000045 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied for safety and efficacy in clinical trials.

What clinical trials is TX000045 in?

TX000045 is being studied in a Phase 2 clinical trial with the identifier NCT07473700. This trial is recruiting participants with pulmonary hypertension due to interstitial lung disease and is being conducted in the United States, Poland, Romania, Serbia, South Korea, and Spain.

Is TX000045 the same as any other drug?

No alternative names for TX000045 have been reported. It is identified solely by its development code TX000045 in clinical trial registries and scientific literature.